Adults with overactive bladder ( OAB ) symptoms for > 3 months and 1 urgency urinary incontinence ( UUI ) episode and 8 micturitions per 24 hours at baseline were randomized to fesoterodine ( 8 mg ) , tolterodine extended-release ( 4 mg ) , or placebo in two 12-week , double-blind , head-to-head studies .